0000899243-20-013636.txt : 20200519 0000899243-20-013636.hdr.sgml : 20200519 20200519204632 ACCESSION NUMBER: 0000899243-20-013636 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200513 FILED AS OF DATE: 20200519 DATE AS OF CHANGE: 20200519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAWES KAREN A CENTRAL INDEX KEY: 0001261506 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 20895472 MAIL ADDRESS: STREET 1: 579 BELLEVUE AVE CITY: NEWPORT STATE: RI ZIP: 02840 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-13 0 0000730272 REPLIGEN CORP RGEN 0001261506 DAWES KAREN A C/O REPLIGEN CORPORATION 41 SEYON ST., BLDG 1, STE 100 WALTHAM MA 02453 1 0 0 0 Common Stock 2020-05-13 4 A 0 722 0.00 A 121556 D Common Stock 2020-05-18 4 S 0 712 135.76 D 120844 D Common Stock 2020-05-18 4 S 0 160 136.92 D 120684 D Common Stock 2020-05-18 4 S 0 269 138.60 D 120415 D Common Stock 2020-05-18 4 S 0 122 139.32 D 120293 D Common Stock 2020-05-18 4 S 0 180 140.62 D 120113 D Common Stock 2020-05-18 4 S 0 77 141.45 D 120036 D Common Stock 2020-05-18 4 S 0 80 142.45 D 119956 D Stock Option (Right to Buy) 128.18 2020-05-13 4 A 0 1761 0.00 A 2021-05-13 2030-05-13 Common Stock 1761 1761 D Ms. Dawes was awarded 722 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 13, 2021. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. $135.76 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.26 to $136.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $138.60 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.94 to $138.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $139.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.11 to $139.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $140.62 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.21 to $140.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $141.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.42 to $142.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Award vests in full one year from grant date on May 13, 2021. /s/ Jeffrey P. Leduc (Attorney in Fact) 2020-05-19